Friends! In this video, I'm going to discuss 2 growth stocks that im buying in this market.
2 extracted signals · 2 resolved · 0 still active
The Patient InvestorIndependent analyst profile- Source published
- 24 Nov 2025, 22:44 UTC
- Recorded by Tahlil Plus
- 18 May 2026, 20:23 UTC

AI-generated source summary
The analysis covers SOFI, HIMS, and NVDA. SOFI and HIMS are identified as undervalued growth stocks with significant upside potential, despite recent price drops and volatility. SOFI's strong member growth and transition to a fee-based model are highlighted, while HIMS's rapid expansion across various health sectors and its lean business model are seen as positive indicators. NVDA is noted for its recent performance with a forecast for continued bearish momentum, although the speaker does not provide specific entry or exit points for NVDA.
AI-generated summary based on the source content.
Signal outcomes at a glance
Evaluation CompleteSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
2 eligible signals linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
The Patient Investor
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.

